First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

BACKGROUND: Limited data exist on outcomes for metastatic renal cell carcinoma (mRCC) patients treated with multiple lines of therapy. Benchmarks for survival are required for patient counselling and clinical trial design. METHODS: Outcomes of mRCC patients from the International mRCC Database Conso...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, J J, Choueiri, T K, Rini, B I, Lee, J-L, Kroeger, N, Srinivas, S, Harshman, L C, Knox, J J, Bjarnason, G A, MacKenzie, M J, Wood, L, Vaishampayan, U N, Agarwal, N, Pal, S K, Tan, M-H, Rha, S Y, Yuasa, T, Donskov, F, Bamias, A, Heng, D Y C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992507/
https://www.ncbi.nlm.nih.gov/pubmed/24691425
http://dx.doi.org/10.1038/bjc.2014.25

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992507/
https://www.ncbi.nlm.nih.gov/pubmed/24691425
http://dx.doi.org/10.1038/bjc.2014.25

Ejemplares similares